share_log

Unveiling 6 Analyst Insights On Nurix Therapeutics

Unveiling 6 Analyst Insights On Nurix Therapeutics

揭示了關於nurix therapeutics的6個分析師見解
Benzinga ·  10/12 01:03
In the preceding three months, 6 analysts have released ratings for Nurix Therapeutics (NASDAQ:NRIX), presenting a wide array of perspectives from bullish to bearish.
在過去的三個月中,有6位分析師爲Nurix Therapeutics(納斯達克:NRIX)發佈了評級,提出了從看好到看淡的各種觀點。
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
下表提供了他們最近評級的精簡視圖,顯示了過去30天的不同情緒,並將其與前幾個月進行比較。
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $33.17, along with a high estimate of $41.00 and a low estimate of $27.00. Witnessing a positive shift, the current average has risen by 28.82% from the previous average price target of $25.75.
爲了提供更深入的見解,分析師已經制定了12個月的價格目標,顯示平均目標爲33.17美元,高估值爲41.00美元,低估值爲27.00美元。目前的平均價格目標比之前的25.75美元上漲了28.82%,呈現出積極的變化。
Interpreting Analyst Ratings: A Closer Look
解讀分析師評級:更深入的了解
The standing...
通過...

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論